Cardiol Therapeutics Inc. CRDL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.33% | -20.97% | -24.20% | -17.43% | 31.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.24% | -11.22% | -16.41% | -7.86% | 23.08% |
| Operating Income | 10.24% | 11.22% | 16.41% | 7.86% | -23.08% |
| Income Before Tax | 8.52% | -2.20% | 9.62% | 6.33% | -24.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.52% | -2.20% | 9.62% | 6.33% | -24.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.52% | -2.20% | 9.62% | 6.33% | -24.60% |
| EBIT | 10.24% | 11.22% | 16.41% | 7.86% | -23.08% |
| EBITDA | 9.70% | 10.64% | 15.83% | 7.27% | -22.98% |
| EPS Basic | 28.77% | 18.08% | 25.53% | 22.99% | -7.15% |
| Normalized Basic EPS | 28.77% | 18.07% | 25.51% | 23.00% | -7.17% |
| EPS Diluted | 28.77% | 18.08% | 25.53% | 22.99% | -7.15% |
| Normalized Diluted EPS | 28.77% | 18.07% | 25.51% | 23.00% | -7.17% |
| Average Basic Shares Outstanding | 28.87% | 24.11% | 21.55% | 21.91% | 18.76% |
| Average Diluted Shares Outstanding | 28.87% | 24.11% | 21.55% | 21.91% | 18.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |